Views & Analysis What HCPs say about Roche's breast cancer drug The online conversations about breast cancer drug Kadcyla before it was approved by NICE.
Views & Analysis How healthcare professionals engage NICE online NICE is reaching out and engaging more via social media.
Views & Analysis What doctors say about Obamacare after US election Daniel Ghinn has been listening to the social media conversations of HCPs.
Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
Views & Analysis What doctors say about Theresa May’s reappointment of Jeremy... Reactions of healthcare professionals to Jeremy Hunt staying as Health Secretary.
Views & Analysis What doctors say about the EU referendum Daniel Ghinn tunes into the conversation around the EU referendum, which takes place on Thursday
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
